Neuroscientific Biopharmaceuticals Ltd. · ASX:NSB

Neuroscientific Biopharmaceuticals — Investor Presentation (February 2023)

14 slides from Neuroscientific Biopharmaceuticals's investor presentation, Feb 3, 2023

  1. Slide 1: ASX Announcement: Investor Update Webinar Presentation

    ASX ANNOUNCEMENT 3 FEBRUARY 2023 INVESTOR UPDATE WEBINAR PRESENTATION For personal use only NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) (“NeuroScientific” or “the Company”) wishes to advise shareholders and investors that the Company will be conducting a live investor update on Friday 3rd Febru

  2. Slide 2: About NeuroScientific Biopharmaceuticals Ltd and EmtinB

    About NeuroScientific Biopharmaceuticals Ltd NeuroScientific Biopharmaceuticals Limited (ASX: NSB) is a company developing peptide- based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company’s product portfolio includes EmtinBTM, a the

  3. Slide 3: Novel Drug Therapies for Neurodegenerative Conditions

    For personal use only NOVEL DRUG THERAPIES FOR NEURODEGENERATIVE CONDITIONS December Quarterly PRESENTATION FEBRUARY 2023 • ASX: NSB neuroscientific.com

  4. Slide 4: Disclaimer

    DISCLAIMER For personal use only The purpose of the presentation is to provide an update of the business of NeuroScientific Biopharmaceuticals Ltd (“NeuroScientific”, or “the Company”). These slides have been prepared as a presentation aid only and the information they contain may require further ex

  5. Slide 5: Leadership & Management

    LEADERSHIP & MANAGEMENT For personal use only BOARD & MANAGEMENT Paul Rennie Dr Anton Uvarov Stephen Quantrill Chairman & Interim CEO Non-Executive Director Non-Executive Director • Founder & Managing Director of • Director of Actinogen (ASX: ACW) • 20+ years corporate advisory Paradigm (ASX: PAR) •

  6. Slide 6: New Patent Filed

    NEW PATENT FILED For personal use only NSB has filed a new patent for EmtinB® to be used in combination with Copaxone® as a possible therapy for Multiple Sclerosis (MS). • Copaxone® • registered for relapsing remitting MS and marketed in 50+ countries. • Peak sales approximately USD$1b, down to USD$

  7. Slide 7: Executive Changes

    EXECUTIVE CHANGES For personal use only • Paul Rennie appointed as interim CEO • Serving this role concurrently with his role as Managing Director of Paradigm Pharmaceuticals (ASX:PAR). • Search for Permanent CEO is ongoing • Dr Anton Uvarov • Moved from Executive Director to Non-Executive Director.

  8. Slide 8: Approval of R&D Advance and Overseas Finding

    APPROVAL OF R&D ADVANCE AND OVERSEAS FINDING NSB has received approval for an advance and overseas finding For personal use only under the R&D Tax Incentive program for preclinical efficacy studies focused on Multiple Sclerosis (MS) • Rebates • Up to 1.62M for costs associated with preclinical MS an

  9. Slide 9: Looking to a Phase I Clinical Trial Submission

    LOOKING TO A PHASE I CLINICAL TRIAL SUBMISSION For personal use only • Safety: • Toxicology reviews complete by 2 x independent toxicologist. • Formulation evolution is underway and close to completion to ensure injectable product has the highest chance of tolerability for clinical trials and next a

  10. Slide 10: Looking to a Phase I Clinical Trial Submission

    LOOKING TO A PHASE I CLINICAL TRIAL SUBMISSION For personal use only • Purity of EmtinB® • Extensive analysis of all EmtinB® batches complete. • Thorough impurity identification to enable qualification of impurities complete. • Regulatory position paper close to completion for a European Scientific

  11. Slide 11: Looking to a Phase I Clinical Trial Submission

    LOOKING TO A PHASE I CLINICAL TRIAL SUBMISSION For personal use only • Efficacy : • NSB will present efficacy data on the preclinical multiple sclerosis model. The data and the final report are due from the external provider the end of this month • NSB has designed and has signed a work order for a

  12. Slide 12: Quarterly Cash Flow

    QUARTERLY CASH FLOW For personal use only NSB cash position was $3.33 million as at end December 2022. The Company has maintained a strong cash position during the initial execution of its R&D program and corporate expenses continue to be carefully managed. • Operating Cash Flows for December 2022 q

  13. Slide 13: EmtinB: Potential disease-modifying treatment for all stages of MS

    EMTINBTM Potential disease-modifying treatment for all stages of MS For personal use only STIMULATES CELL PROMOTES AXONAL REGULATES PROMOTES SURVIVAL PATHWAYS REGENERATION INFLAMMATION REMYELINATION Activates cell survival Activation of LRP-1 also Downregulates Stimulates proliferation and pathways

  14. Slide 14: For more information contact

    For personal use only neuroscientific.com For more information contact: Paul Rennie– Interim CEO E: [email protected]

NeuroScientific Biopharmaceuticals — Investor Presentation (February 2023) on 6ix